NATCO Pharma Limited (NSE:NATCOPHARM)
826.00
-8.20 (-0.98%)
Oct 24, 2025, 12:58 PM IST
NATCO Pharma Revenue
NATCO Pharma had revenue of 13.29B INR in the quarter ending June 30, 2025, a decrease of -2.47%. This brings the company's revenue in the last twelve months to 43.96B, up 1.08% year-over-year. In the fiscal year ending March 31, 2025, NATCO Pharma had annual revenue of 44.32B with 10.74% growth.
Revenue (ttm)
43.96B
Revenue Growth
+1.08%
P/S Ratio
3.40
Revenue / Employee
10.47M
Employees
4,199
Market Cap
149.41B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 44.32B | 4.30B | 10.74% |
| Mar 31, 2024 | 40.02B | 12.94B | 47.76% |
| Mar 31, 2023 | 27.09B | 7.62B | 39.17% |
| Mar 31, 2022 | 19.46B | -1.10B | -5.35% |
| Mar 31, 2021 | 20.56B | 1.41B | 7.37% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 537.77B |
| Aurobindo Pharma | 320.25B |
| Cipla | 274.80B |
| Zydus Lifesciences | 236.08B |
| Apollo Hospitals Enterprise | 225.51B |
| Glenmark Pharmaceuticals | 134.56B |
| Alkem Laboratories | 133.04B |
| Mankind Pharma | 129.10B |
NATCO Pharma News
- 12 days ago - Pharma expansion: Natco to acquire major stake in South Africa’s Adcock Ingram, firm to go private - The Times of India
- 4 weeks ago - Natco Pharma board approves evaluation of Agro business demerger - Business Upturn
- 5 weeks ago - Natco Pharma receives US FDA’s VAI classification for Hyderabad unit - Business Upturn
- 6 weeks ago - Natco Pharma moves closer to Adcock Ingram acquisition with shareholder vote set for October - Business Upturn
- 2 months ago - Natco Pharma launches generic Bosentan tablets for oral suspension in the US with 180-day exclusivity - Business Upturn
- 2 months ago - Lupin launches Bosentan Tablets for Oral Suspension in US with 180-day exclusivity - Business Upturn
- 2 months ago - Brokerage recommendations for August 14: Muthoot Finance, Va Tech Wabag, JSPL, VMM, BPCL, Devyani, Apollo Hospitals, HDFC Life, Infosys, Brainbees, United Spirits, Motherson, Jubilant Food, PI Industries, Natco Pharma, ONGC in focus - Business Upturn
- 2 months ago - Natco Pharma board declares interim dividend of Rs 2 per share for FY26 - Business Upturn